Leukotrienes in asthma: The potential therapeutic role of antileukotriene agents

Archives of Internal Medicine

Volumn 156, Issue 19, 1996, Pages 2181-2189

  Smith, Lewis J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 METHOXY 1 [3 (2 NAPHTHYLMETHOXY)PHENYL]PROPYL]THIAZOLE; 2 [4 [2 (5 TETRAZOLYLMETHYL)BENZYLOXY]PHENOXYMETHYL]QUINOLINE; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLSULFONYL] 3 OXO 4 PHENYLBUTYRIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLTHIO]PHENYL] 4 HYDROXY 3 METHYLBUTYRIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; CINALUKAST; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PABILUKAST; PIRIPROST; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ASTHMA; DRUG EFFECT; DRUG EFFICACY; HUMAN; INFLAMMATION; LUNG FUNCTION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; HUMANS; HYDROXYUREA; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; TOSYL COMPOUNDS;

EID: 0029809520     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.19.2181     Document Type: Review

References (95)

1. Barnes PJ. A new approach Io the treatment of asthma. N Engl J Med. 1989;321:1517-1527.
2. McFadden ER Jr, Gilbert IA. Asthma. N Engl J Med. 1992;327:1928-1937.
3. National Asthma Education Program. Guidelines for the Diagnosis and Management of Asthma. Washington, DC: US Dept of Health and Human Services; August 1991. Publication 91-3042.
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225-244.
5. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990;142:434-457.
6. Guidelines on the management of asthma. Thorax. 1993;48:S1-S24.
7. Holgate S. Mediator and cytokine mechanisms in asthma. Thorax. 1993;48:103-109.
8. 1 blocker, chlorpheneramine. J Allergy Clin Immunol. 1977; 59:54-63.
9. 1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax. 1987; 42:946-952.
10. Samter M, Beers FR Jr. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968;68:975-983.
11. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol Cogn Med Sci. 1940;30:121-145.
12. Brocklehurst WE. Slow reacting substances and related compounds. Prog Allergy. 1962;6:539-558.
13. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A. 1979;76:4275-4279.
14. Morris HR, Taylor GW, Piper PF, Tippins JR. Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature. 1980;285:104-106.
15. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. Slow-reading substance of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A. 1980;77:3710-3714.
16. 2 and its regulatory factors. Adv Exp Med Biol. 1990;279:1-22.
17. 4. Proc Natl Acad Sci U S A. 1982;79:7866-7870.
18. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils. Proc Natl Acad Sci U S A. 1983; 80:7626-7630.
19. Tudhope SR, Cuthberl NJ, Abram TS, et al. Bay u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol. 1994;264:317-323.
20. 4. J Pharmacol Exper Ther. 1986;237:558-562.
21. 4 receptor in guinea pig lung. Proc Natl Acad Sci U S A. 1983;80:7615-7619.
22. Labat C, Ortiz JL, Norel X, et al. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther. 1992;263:800-805.
23. Dahlen S-E, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980;288:484-486.
24. 4. Proc Natl Acad Sci U S A. 1983;80:1712-1716.
25. Samuelsson B. Leukotrienes: mediators of hypersensitivity reactions and inflammation. Science. 1983;220:568-575.
26. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med. 1994;121:684-697.
27. Baud L, Perez J, Denis M, Ardaillou R. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J Immunol. 1987;138:1190-1195.
28. Palmerg L, Claesson H-E, Thyberg J. Leukotrienes stimulate initiation of DNA synthesis in cullured arterial smooth muscle. J Cell Sci. 1987; 88:151-159.
29. Leikauf GD, Claesson H-E, Doupnik CA, Hybbinette S, Grafstrom RC. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am J Physiol. 1990;259:L255-L261.
30. Arm JP, Lee TH. Sulfidopeptide leukotrienes in asthma. Clin Sci. 1993;84:501-510.
31. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J. 1995;8:1203-1213.
32. Weiss JW, Drazen JM, Coles N, et al. Broncho-constrictor effects of leukotriene C in humans. Science. 1982;216:196-198.
33. Griffin M, Weiss JW, Leitch AG, et al. Effects of leukotriene D on the airways in asthma. N Engl J Med. 1983;308:436-439.
34. 4, and histamine in normal human subjects. Thorax. 1984;39:500-504.
35. 4 in humans. Am Rev Respir Dis. 1985;131: 368-372.
36. 4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986; 315:480-484.
37. 4 in normal subjects. Am Rev Respir Dis. 1986;133:1127-1132.
38. 4 in normal subjects. Am Rev Respir Dis. 1987;136:979-984.
39. 4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis. 1991;144:1053-1057.
40. 4 and granulocytic infiltration into asthmatic airways. Lancet. 1993; 341:989-990.
41. Salari H, Borgeat P, Fournier M, Hebert J, Pelletier G. Studies on the release of leukotrienes and histamine by human lung parenchyma and bronchial fragments upon immunologic and non-immunologic stimulation. J Exp Med. 1985;162: 1904-1915.
42. Schleimer RP, MacGlashan DW Jr, Peters SP, Pinckard RN, Adkinson NF Jr, Lichtenstein LM. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis. 1986;133:614-617.
43. 4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989; 84:19-26.
44. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 1990;142:112-119.
45. 4 levels following allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis. 1991;144:1411-1413.
46. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis. 1992; 146:104-108.
47. 4 and histamine in asthmatics. Am Rev Respir Dis. 1992;146:96-103.
48. McMillan RM, Walker ERH. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci. 1992;13:323-330.
49. Mann JS, Robinson C, Sheridan AZ, Clement P, Bach MK, Holgate ST. Effect of inhaled piriprost (U-60,257), a novel leukotriene inhibitor, on allergen and exercise-induced bronchoconstriction in asthma. Thorax. 1986;41:746-752.
50. 4-induced bronchoconstriction in normal man. J Allergy Clin Immunol. 1987;79:816-821.
51. 4 antagonist L-649,923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol. 1987;79:811-816.
52. 4 in atopic subjects. J Allergy Clin Immunol. 1989;83:939-944.
53. Israel E, Juniper EF, Callaghan JT, et al. Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis. 1989;140:1348-1353.
54. Evans JM, Barnes NC, Zakrzewaki JT, et al. L-648,051, a novel cysteinyl-leukotriene antagonist, is active by the inhaled route in man. Br J Clin Pnarmacol. 1989;28:125-135.
55. Bel EH, Timmers MC, Dijkman JH, Stahl EG, Sterk PJ. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol. 1990;85:1067-1075.
56. 4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis. 1989;140:1336-1339.
57. 4-induced bronchoconstriction in the human. Am Rev Respir Dis. 1991;144:617-621.
58. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 1992;146:358-363.
59. 4 antagonist, MK-679. Am Rev Respir Dis. 1993;147:1442-1446.
60. Welch MJ, Nelson HS, Paull BR, Smith JA, Feiss G, Tobey RE. Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults. Ann Allergy. 1994;72:348-352.
61. 4-receptor antagonist. N Engl J Med. 1990;323:1736-1739.
62. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992;90:193-201.
63. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219: a peptide leukotriene antagonist. Am Rev Respir Dis. 1990; 141:978-987.
64. 4-induced bronchoconstriction in normal subjects by the oral leukotriene receptor antagonist ICI 204,219. Am Rev Respir Dis. 1990;141:988-992.
65. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther. 1993;54: 430-436.
66. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991;337:690-694.
67. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol. 1992; 89:1040-1045.
68. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis. 1993;147:1431-1435.
69. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchocon-striction in subjects with bronchial asthma. Chest. 1994;105:483-488.
70. Dahlen B, Zetterstrom O, Bjorck, Dahlen SE. The leukotriene-antagonist ICI 204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J. 1994;7:324-331.
71. 4 receptor antagonist. Am Rev Respir Dis. 1992;145:746-749.
72. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis. 1993;147:1413-1418.
73. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med. 1994;150:618-623.
74. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 1990; 323:1740-1744.
75. Fischer AR, McFadden CA, Frantz R, et al. Effect of chronic 5-lipoxypenase inhibition on airway hyperresponsiveness. Am J Respir Crit Care Med. 1995;152:1203-1207.
76. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153:931-935.
77. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 1991;46: 184-189.
78. Nasser SMS, Bell GS, Hawksworth RJ, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax. 1994;49:743-748.
79. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993;147:839-844.
80. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann intern Med 1993;119: 1059-1066.
81. Israel E, Conn J, Dube L, Drazen JM, and the Zileuton Study Group. Effect of treatment wih zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA. 1996;275:931-936.
82. Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxy-genase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med. 1995;152:897-905.
83. Lee TH. Mechanisms of aspirin sensitivity. Am Rev Respir Dis. 1992;145(suppl):S34-S36.
84. Szczeklik A, Grygiewski RJ, Czemiawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ. 1975;1: 67-69.
85. 4 release from activated neutrophils. Proc Natl Acad Sci U S A. 1983; 80:4349-4353.
86. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143:1025-1029.
87. 4 during aspirin-induced asthma. J Lab Clin Med 1992;119:48-51.
88. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin-sensitive asthmatic subjects. Thorax, 1993; 48:1205-1210.
89. Nasser SMS, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax. 1994;49:749-756.
90. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis. 1991;144:957-958.
91. Dahlen B, Kumiin M, Margolskee DJ, et al. The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J. 1993;6:1018-1026.
92. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148:1447-1451.
93. Yamamoto H, Nagata M, Kuramitsu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist 0N0-1078. Am J Respir Crit Care Med. 1994;150:254-257.
94. Chen X-S, Shelier JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature. 1994;372: 179-182.
95. Holroyde MC, Altounyan REC, Cole M, Dixon M, Elliot EV. Bronchoconstriction produced in man by leukotrienes C and D. Lancet. 1981; 2:17-18.